Hope S. Rugo
A5090188675- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Peptidase Inhibition and Analysis
- Cancer-related cognitive impairment studies
University of California, San Francisco
2016-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2016-2025
Twitter (United States)
2024
Dana-Farber Cancer Institute
2010-2023
Sarah Cannon
2009-2023
Tennessee Oncology
2011-2023
Memorial Sloan Kettering Cancer Center
2005-2023
City College of San Francisco
2019-2023
The University of Texas MD Anderson Cancer Center
2005-2023
Massachusetts General Hospital
2014-2023
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of atezolizumab.
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target rapamycin (mTOR) intracellular signaling pathway. In early studies, mTOR inhibitor everolimus added showed antitumor activity.In this phase 3, randomized trial, we compared and exemestane versus placebo (randomly assigned a 2:1 ratio) 724 patients hormone-receptor-positive advanced who had recurrence or progression while receiving previous nonsteroidal aromatase adjuvant setting treat...
A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than alone in the initial treatment of postmenopausal women estrogen-receptor (ER)–positive, human epidermal growth factor receptor (HER2)–negative advanced breast cancer. We performed a 3 designed to confirm and expand efficacy safety data for this indication.
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity early studies.
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations BRCA1 BRCA2 ( BRCA1/2).We conducted a randomized, open-label, phase 3 trial which BRCA1/2 mutation were assigned, 2:1 ratio, to receive (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, vinorelbine continuous 21-day cycles). primary end point was progression-free survival,...
Immune-regulated pathways influence multiple aspects of cancer development. In this article we demonstrate that both macrophage abundance and T-cell in breast represent prognostic indicators for recurrence-free overall survival. We provide evidence response to chemotherapy is part regulated by these leukocytes; cytotoxic therapies induce mammary epithelial cells produce monocyte/macrophage recruitment factors, including colony stimulating factor 1 (CSF1) interleukin-34, which together...
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients metastatic breast cancer previously treated an anthracycline taxane.Patients were randomly assigned receive (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone combination bevacizumab (15 mg/kg) 1. The primary end point was progression-free survival (PFS), as determined by independent review...
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which expressed in majority cancers, coupled to SN-38 (topoisomerase I inhibitor) through proprietary hydrolyzable linker.
Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than single agent alone. EGF104900 compared the activity of alone or combination with trastuzumab patients ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients Methods MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either...
Answer questions and earn CME/CNE The revision of the eighth edition primary tumor, lymph node, metastasis (TNM) classification American Joint Commission Cancer (AJCC) for breast cancer was determined by a multidisciplinary team experts. panel recognized need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen progesterone receptor expression, human epidermal growth factor 2 (HER2) gene expression prognostic panels into staging system. AJCC levels evidence...
Biomarkers that can predict response to anti-programmed cell death 1 (PD-1) therapy across multiple tumor types include a T-cell-inflamed gene-expression profile (GEP), programmed ligand (PD-L1) expression, and mutational burden (TMB). Associations between these biomarkers the clinical efficacy of pembrolizumab were evaluated in trial encompassed 20 cohorts patients with advanced solid tumors.KEYNOTE-028 ( ClinicalTrials.gov identifier: NCT02054806) is nonrandomized, phase Ib enrolled 475...
Cancer-related fatigue is defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer treatment that not proportional recent activity and interferes with usual functioning. It one the most common side effects in patients cancer. Fatigue has been shown be consequence active treatment, but it may also persist into posttreatment periods. Furthermore, difficulties end-of-life care can compounded by fatigue. The NCCN...
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic activity of trastuzumab with targeted delivery a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2)-overexpressing cancer cells. Based on results from phase I study that showed T-DM1 was well tolerated at maximum-tolerated dose 3.6 mg/kg every 3 weeks, evidence efficacy, in patients HER2-positive metastatic breast (MBC) who were previously treated trastuzumab, we conducted II further...
Standard chemotherapy is associated with low response rates and short progression-free survival among patients pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), SN-38, conjugated to antibody by cleavable linker. enables delivery of high concentrations SN-38 tumors.
Patients with hormone receptor-negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset androgen receptor (AR) expression is predicted to respond antiandrogen This phase II study explored bicalutamide in AR-positive, estrogen (ER), and progesterone (PgR)-negative metastatic cancer.Tumors patients ER/PgR-negative advanced were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered positive]. If either the primary or...